

## MINIMAL LEUKOCYTES PHENOTYPING PANEL IN PATIENTS WITH COVID-19

Radoslava Emilova<sup>1</sup>, Valentina Atanasova<sup>2</sup>, Yana Todorova<sup>1</sup>, Yana Krasteva<sup>2</sup>, Spaska Lisichkova<sup>2,4</sup>,  
Anastasiya Mihaylova<sup>2</sup>, Elissaveta Naumova<sup>2,4</sup>, Maria Nikolova<sup>1</sup>, Hristo Taskov<sup>3</sup>

<sup>1</sup>*NRL of Immunology, National Centre for Infectious and Parasitic Diseases, Sofia, Bulgaria*

<sup>2</sup>*Clinic of Clinical Immunology with Stem Cell Bank, University Hospital "Alexandrovska", Sofia, Bulgaria*

<sup>3</sup>*Department of Microbiology and Immunology, Medical University, Plovdiv, Bulgaria*

<sup>4</sup>*Department of Clinical Immunology, Faculty of Medicine, Medical University, Sofia, Bulgaria*

SARS-CoV-2 causes dysregulation of immune response associated with unpredictable clinical course. Multiparameter flow cytometry is the most accessible method for immune monitoring.

**Aim.** Evaluation of minimal flow cytometry panel for monitoring of SARS-CoV-2 infection, including the major T lymphocyte populations and activated subsets.

**Material and methods.** Blood samples from COVID-19 patients (n=69) aged 50 (18-80) years were studied. The absolute numbers (AC) and percentages of lymphocyte subpopulations were determined by flow cytometry using CD3/CD8/CD45/CD4, CD8/CD38/CD3/HLA-DR and standard TRUCount tubes (BD Biosciences, FACSCanto II). Specific IgA and IgG antibodies were determined by Anti-SARS-CoV-2 ELISA (Euroimmun).

**Results.** 42 men and 27 women with mild/moderate symptoms were tested 6±4 days after the positive PCR. Men were significantly younger (mean 46 vs. 57y respectively, p<0.05). The AC and percentage of total T (CD3+CD19-), Th (CD3+CD4+), Tc (CD3+CD8+) as well as the CD4/CD8 index did not differ significantly from the reference values. CD38+, HLA-DR+, CD38+/HLA-DR+CD4 or CD8T shares were significantly increased: 22.5vs.14.8, 3.7vs.1.7, 2.1vs.0.7 and 6.8vs.2.8, 3.1vs.1.0, 2.0vs.0.4, (p<0.05 for all). The percentage of CD38+CD4 and CD38+CD8T decreased after the 14th day (24.7vs.19.7, p<0.038; 9.7vs.5.2,p<0.05). HLA-DR+CD8+T correlated with IgG levels (R=0.55, p<0.001). Patients <50y of age were characterized with higher proportion and AC of CD8T (25vs.19%, p<0.01; 430vs.299cells/μl, p<0.05), lower CD4/CD8 ratio (1.9vs.2.6, p<0.01), and a higher share of CD38+CD4 and CD8T (25vs.20% and 11vs.6.0%, p<0.01 for both) regardless of the infection duration. In younger patients, the share of CD38+CD4 and CD8T correlated inversely with SARS-CoV-2IgA (R=-0.50, p<0.05, for both).

**Conclusions.** CD38+/HLA-DR+CD4 and CD8T are sensitive age-related parameters for immune monitoring of COVID-19. The pathogenetic significance of each activated subset needs to be clarified, especially in the context of the published data on the suppressive effect of a CD38+CD8T.